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ABSTRACT:
The promise of PARP-inhibitors(PARPis) in the management of epithelial 
ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients 
with homologous recombination (HR)-proficient tumors do not respond well to 
these agents. Combination of PARPis with agents that inhibit HR may represent 
an effective strategy to enhance their activity in HR-proficient tumors. Using a 
bioinformatics approach, we identified that heat shock protein 90 inhibitors(HSP90i) 
may suppress HR and thus revert HR-proficient to HR-deficient tumors. Analysis 
of publicly available gene expression data showed that exposure of HR-proficient 
breast cancer cell lines to HSP90i 17-AAG(17-allylamino-17-demethoxygeldanamycin) 
downregulated HR, ATM and Fanconi Anemia pathways. In HR-proficient EOC cells, 
17-AAG suppressed HR as assessed using the RAD51 foci formation assay and this was 
further confirmed using the Direct Repeat-GFP reporter assay. Furthermore, 17-AAG 
downregulated BRCA1 and/or RAD51 protein levels, and induced significantly more 
γH2AX activation in combination with olaparib compared to olaparib alone. Finally, 
sublethal concentrations of 17-AAG sensitized HR-proficient EOC lines to olaparib 
and carboplatin but did not affect sensitivity of the HR-deficient OVCAR8 line arguing 
that the 17-AAG mediated sensitization is dependent on suppression of HR. These 
results provide a preclinical rationale for using a combination of olaparib/17-AAG in 
HR-proficient EOC.
INTRODUCTION
Epithelial ovarian cancer (EOC) is characterized 
by frequent genetic and epigenetic alterations in gene 
members of the homologous recombination (HR) 
DNA repair pathway. In particular, approximately 
50% of high grade serous cancers harbor molecular 
alterations in the HR pathway which include germline 
and somatic BRCA1/2 mutations in 15% and 6-7% of 
them respectively [1, 2]. HR deficient tumors are highly 
sensitive to platinum analogues and other cytotoxic drugs 
that induce double strand DNA breaks which are normally 
repaired by HR. These tumors are also highly sensitive to 
poly-ADP ribose polymerase inhibitors (PARPis), a novel 
class of anticancer agents, which exhibit synthetic lethality 
in tumors with defective HR pathway [3-5]. PARPis have 
shown striking activity in HR-deficient EOC tumors both 
in the presence [6-8] and in the absence of BRCA1 or 
BRCA2 mutations [9, 10]. Of these agents, olaparib has 
been the most widely studied PARPi and is currently in the Oncotarget 2679 www.impactjournals.com/oncotarget
most advanced stage of clinical development [6, 7, 9-11]. 
The promise of PARP inhibitors in the management 
of EOC is tempered by the fact that HR-proficient EOCs 
do not respond well to these agents, suggesting that the 
remaining approximately 50% of EOC patients (i.e. those 
without HR alterations) do not benefit from this novel 
class of drugs. Combination of PARPis with agents that 
inhibit HR may represent an effective strategy to enhance 
activity  of  PARPis  in  HR  proficient  tumors  and  thus 
potentially expand use of these agents beyond patients 
with HR deficient EOCs. 
In order to identify candidate agents that may 
directly or indirectly inhibit HR, we used the Connectivity 
Map, a reference collection of gene expression signatures 
that have been generated by exposing cultured human 
cell lines to a variety of small molecule drugs[12, 13]. 
By matching gene expression signatures of disease 
states or physiological processes with gene expression 
signatures of small molecule drugs, the Connectivity Map 
has successfully unraveled novel functional associations 
between small molecules sharing a mechanism of action, 
chemicals and physiological processes, and diseases 
and drugs. Here, we report that, using the Connectivity 
Map  we  identified  heat  shock  protein  90  inhibitors 
(HSP90i) as candidate drugs that suppress HR, and then 
confirmed experimentally that an HSP90i 17-AAG[14, 
15] suppresses HR pathway, and enhances sensitivity to 
platinum and PARPis in HR proficient ovarian cancer 
cells.
RESULTS
Connectivity Map identifies HSP90is as candidate 
compounds that suppress HR 
We queried a previously developed gene expression 
signature of BRCAness[16] to the Connectivity Map in 
order to identify matching gene expression signatures 
of small molecule drugs (Figure 1A). Because of the 
FIGURE 1: Application of BRCAness signature into Connectivity Map identifies HSP90 inhibitors as candidate 
compounds that may suppress HR. (A) Schematic of the bioinformatics approach used to identify candidate compounds that may 
suppress of HR. (B) Top ranked compounds, enrichment, permutation p and specificity values as determined by query of the top performing 
genes of the BRCAness signature. (C) Connectivity mapping of geldanamycin and alvespimycin. The barview is constructed from 6,100 
horizontal lines, each representing an individual treatment instance, ordered by their corresponding connectivity scores with geldanamycin 
(left) and alvespimycin (right). All geldanamycin and alvespimycin instances are colored in black bars. Colors applied to the remaining 
instances (i.e. gene expression profiles of the cells obtained with other than geldanamycin and alvespimycin) reflect the sign of their scores 
(green,positive; gray, null; red, negative). The rank, concentration, cell line and connectivity score for geldanamycin and alvespimycin are 
also shown. Oncotarget 2680 www.impactjournals.com/oncotarget
potential association of the BRCAness gene expression 
signature with defective HR, we hypothesized that drugs 
identified via the Connectivity Map whose gene expression 
signatures are similar to the BRCAness signature may be 
functionally associated with induction of defective HR and 
thus reversion of HR proficient to HR deficient tumors. 
Application of the top performing genes of the 
BRCAness signature to the Connectivity Map identified 
a number of interesting compounds (Figure 1B) with 
high connectivity scores across several cell lines included 
in the Connectivity Map (Figure 1C). Of note, the two 
highest performing compounds, which were consistently 
identified using various cut-offs for the top performing 
genes of BRCAness signature, were geldanamycin and 
alvespimycin, both HSP90 inhibitors. This finding raised 
the possibility of a functional relationship between HSP90 
inhibition and induction of deficient HR. In this regard, 
as predicted by the Connectivity Map, we hypothesized 
that these agents might enhance PARPi and platinum 
sensitivity by suppressing HR (either directly or indirectly) 
thereby suggesting that HSP90is may have an off-target 
class effect involving the HR pathway. 
17-AAG downregulates HR pathway and gene 
expression in HR proficient but not HR deficient 
cells
Given that the Connectivity Map identified HSP90is 
as candidate agents that suppress HR, we evaluated 
whether the transcriptional response to HSP90is affects 
HR pathway and HR pathway genes in cancer cell lines. 
We queried GEO for publicly available gene expression 
data of response to HSP90is and identified one microarray 
dataset assessing the transcriptional response of breast 
cancer cell lines to HSP90i 17-AAG (17-allylamino-17-
demethoxygeldanamycin). 17-AAG is an HSP90 inhibitor 
that has been evaluated in clinical trials in various 
malignancies, and is currently in the most advanced stage 
of clinical development of all HSP90is. Furthermore, 
unlike geldanamycin, it is not hepatotoxic and is therefore 
appropriate for clinical use.
This microarray dataset included gene expression 
data  of  the  HR  proficient  (Hs578T,  MCF-7,  MDA-
MB-157, T47D and MDA-MB-231) and HR deficient 
(MBA-MD-436,  HCC-1937  and  UACC3199)  breast 
cancer  cell  lines  exposed  to  17-AAG  or  control.  We 
assessed  17-AAG  induced  changes  in  the  expression 
levels of genes of the HR pathway both at an individual 
gene level and at a global pathway level.
Strikingly, in the HR proficient breast cancer cell 
lines, pathway analysis revealed that exposure to 17-AAG 
statistically significantly downregulated HR (p<0.005), 
ATM (p=0.015) signaling and Fanconi Anemia (p<0.005) 
pathways, which are involved in repair of double strand 
breaks and interstrand crosslinks (Table 1). Furthermore, 
the expression levels of several genes of these pathways 
were  decreased  upon  exposure  to  17-AAG  (Table  1). 
Conversely, in the HR deficient (MBA-MD-436, HCC-
1937 and UACC3199) breast cancer cell lines, 17-AAG 
did not significantly affect any of these pathways (p value 
non significant for all 3 aforementioned pathways).
Sublethal concentrations of 17-AAG suppress HR 
in HR proficient ovarian cancer cell lines
RAD51 is involved in HR, and formation of nuclear 
RAD51 foci after IR has been used as a surrogate of 
effective HR DNA repair. We evaluated the functional 
impact of 17-AAG on HR in HR proficient ovarian cancer 
cell lines using the RAD51 foci formation after ionizing 
radiation (IR) assay. As shown in Figure 2A-2D, sublethal 
concentrations of 17-AAG (as determined by 17-AAG 
dose response curves that were obtained for each ovarian 
cancer cell line, Supplementary Figure 1) had a significant 
impact on RAD51 foci after IR causing approximately 
70% reduction in foci formation in 36M2 and SKOV3 
cells.
To further confirm the results of the RAD51 foci 
formation assay we used the Direct Repeat-GFP (DR-
GFP) reporter system previously developed to assay HR 
in mammalian cells [17, 18]. DR-GFP is an integrated 
fluorescence-based reporter that allows for the efficient 
quantification of HR at a single, targeted DSB by flow 
cytometry or immunofluorescence microscopy. As shown 
in Figure 2E, 17-AAG diminished HR-mediated DSB 
repair in a dose dependent fashion. 
17-AAG downregulates RAD51 and/or BRCA1 
protein levels in ovarian cancer cells 
We evaluated whether 17-AAG downregulates HR 
pathway genes in HR proficient ovarian cancer cell lines 
as predicted by the microarray data in the breast cancer 
cell lines (Table 1). For this purpose, we performed 
Western blot of two representative HR pathway genes, 
RAD51 and BRCA1 that were found to be downregulated 
upon exposure to 17-AAG in HR proficient cells (Table 1). 
As shown in Figure 3A, 17-AAG downregulated protein 
levels of BRCA1 and RAD51 in 36M2 and RAD51 alone 
in SKOV3 ovarian cancer cell lines. 
Sublethal concentrations of 17-AAG combined 
with olaparib induce γH2AX activation more than 
olaparib alone in ovarian cancer cells 
Having  demonstrated  that  17-AAG  functionally 
inhibits  HR,  we  determined  whether  17-AAG  could 
sensitize ovarian cancer cells to the cytotoxic effects of 
PARPi olaparib. We first assessed γH2Ax activation which Oncotarget 2681 www.impactjournals.com/oncotarget
TABLE 1: 17-AAG down-regulates HR pathway genes in HR competent breast and ovarian cancer cells
FIGURE 2: 17-AAG downregulates HR-mediated DSB  repair.  (A-D) Analysis of HR-mediated repair by RAD51 focus 
formation. 36M2 cells (A and B) or SKOV3 cells (C and D) were treated with 17-AAG or vehicle control for 24 hrs, stained for RAD51 
(green) and 4′,6-diamidino-2-phenylindole (DAPI) (blue) 6 h after exposure to IR. The images were captured by fluorescence microscopy 
and RAD51 focus-positive cells (with > 10 foci) were quantified by comparing 100 cells. Mean ± SD of 3 independent experiments is 
graphically represented in Figure 2C and 2E. * indicates p< 0.05. (E) Measurement of HR-mediated repair of an I-SceI induced site specific 
DSB. Cells carrying a single copy of the recombination substrate (DR-GFP) were treated with indicated concentrations of 17-AAG or 
vehicle control for 24 hrs before transfection with I-SceI or control vector. GFP positive cells were analyzed 48 h later by flow cytometry 
(FACS). Mean ± SD of 3 independent experiments is graphically represented. * indicates p< 0.05.
HR competent Breast 
Lines
(Hs578T, MCF-7, 
MDA-MB-157, MDA-
MB-231)
Pathways Up in control vs 17-AAG 
treated cells Pathway P Genes %  Up  in  control  vs  17-AAG 
treated cells
KEGG  HOMOLOGOUS 
RECOMBINATION <0.005  FAA100 69
REACTOME FANCONI ANEMIA 
PATHWAY 0.005 FANCL 68
BIOCARTA  ATM  SIGNALING 
PATHWAY 0.015 RAD51C 58
RPA3 55
BRCA1 50
BLM 50
FANCA 37
FANCC 33
ATR 32
FANCG 31
NBN 28
RAD54L 27
RAD51 22Oncotarget 2682 www.impactjournals.com/oncotarget
is a surrogate of DNA damage and a marker of cytotoxicity 
of ovarian cancer cells. Specifically, we examined whether 
γH2AX expression was enhanced by the combination of 
17-AAG and olaparib compared to olaparib alone. As 
shown in Figure 3B, we confirmed enhanced γH2AX 
expression in the HR proficient ovarian cancer cells 36M2 
and SKOV3 treated with sublethal concentrations of 17-
AAG in combination with olaparib compared to olaparib 
alone. 
17-AAG sensitizes HR proficient ovarian cancer 
cell lines to olaparib and carboplatin in vitro
In  order  to  assess  whether  17-AAG  induces 
sensitivity to olaparib we used only sublethal doses of 
17-AAG as determined in the dose responses curves in 
each cell line (Supplementary Figure 1). As shown in 
Figure  4A,  sublethal  concentrations  of  17-AAG  were 
associated  with  increased  sensitivity  of  HR  proficient 
cell lines SKOV3, OVCAR5 and 36M2 cells to olaparib. 
Furthermore, exposure of these HR proficient ovarian 
cancer cell lines to sublethal concentrations of 17-AAG 
also  enhanced  sensitivity  to  carboplatin  (Figure  4B). 
Finally, viability assays with a combination of three drugs, 
olaparib,  carboplatin,  and  17-AAG,  in  HR-proficient 
ovarian cancer cell lines (36M2 and OVCAR5) showed 
that 17-AAG also enhanced sensitivity to the combination 
of olaparib and carboplatin. Of note, for both OVCAR5 
and 36M2 cells, we were able to detect significant killing 
with very low olaparib and carboplatin doses, i.e. as low 
as 2.5uM (Supplementary Figure 2).
17-AAG does not sensitize HR deficient OVCAR8 
cell line to olaparib and carboplatin in vitro
We  previously  showed  that  17-AAG  suppresses 
HR and enhances sensitivity of HR proficient cell lines 
to olaparib and carboplatin. In order to evaluate the effect 
of 17-AAG in HR deficient ovarian cancer cells, we used 
the OVCAR8 cell line which harbors almost undetectable 
levels of BRCA1 protein (Figure 5A) and very low levels 
of BRCA1 transcript (Figure 5B) compared to 36M2 
ovarian cancer line. As shown in Figure 5C, sublethal 
concentrations of 17-AAG did not sensitize OVCAR8 
cells to olaparib or carboplatin. 
DISCUSSION
Although platinum analogues and PARPis exhibit 
striking activity in HR deficient EOCs, HR proficient 
tumors do not respond well to these agents. Furthermore, 
FIGURE 3: 17-AAG downregulates the genes involved in HR pathway. (A) Expression of HR genes is impacted by 17-AAG. 
Indicated cells were treated with 17-AAG or vehicle control for 24 hrs and washed off before subjected to immunoblotting in another 24 
hrs. Cell lysates were analyzed by immunoblot for BRCA1 or RAD51. Images were quantified by ImageJ software and the mean ± SD of 
3 independent experiments is graphically shown in the lower panel, * indicates p< 0.05. (B) γ-H2AX accumulation after treatment with 
olaparib ± 17-AAG. Indicated cells were treated with olaparib ± 17-AAG for 24 hrs before evaluation of γ-H2AX by immunoblotting. Total 
H2AX was served as loading control for these experiments. * indicates p< 0.05.Oncotarget 2683 www.impactjournals.com/oncotarget
FIGURE 4: 17-AAG sensitizes HR-proficient cells to olaparib and carboplatin. (A and B) Luminescence-based viability 
assay in HR-proficient cells with olaparib or carboplatin. Cells were plated onto a 96-well plate at 1000 cells/well density and treated with 
indicated concentrations of PARP inhibitor, olaparib (A) or platinum drug, carboplatin (B) on the following day. Viability was tested by 
using CellTiter Glo (Promega) in 5 days. Curves were generated from 3 independent experiments.
FIGURE 5: 17-AAG does not sensitize HR-deficient cells to olaparib or carboplatin. (A and B) Validation of undetectable 
levels of BRCA1 expression in OVCAR8 cells. OVCAR8 cells were analyzed for BRCA1 expression by immunoblotting (A) and qRT-
PCR (B) compared to BRCA1-proficient 36M2 cells.(C) Viability assay in HR-deficient cells with PARP inhibitor or platinum drug. 
Viability assay was done in the same way as in Figure 4.Oncotarget 2684 www.impactjournals.com/oncotarget
acquired  resistance  to  PARPis  in  HR  deficient  EOCs 
frequently occurs via restoration of HR; for example, 
BRCA1/2-mutated  EOCs  become  HR  proficient  via 
secondary BRCA1/2 mutations that restore BRCA1/2 
function and lead to PARPi and platinum resistance [19-
23]. Therefore, combination of PARPis with agents that 
inhibit HR may represent an effective strategy to enhance 
activity of PARPis in EOCs that are HR proficient either 
at baseline or at the time of development of platinum or 
PARPi resistance. In this regard, CDK1 inhibitors and 
PI3K inhibitors, which inhibit HR, have been shown to 
sensitize HR proficient cells to PARP inhibitors [24, 25]. 
In this study, we used a unique bioinformatics 
approach to identify novel candidate agents that have the 
potential to suppress HR and thus revert HR proficient 
to HR deficient tumors. Application of our previously 
developed, publicly available, BRCAness signature to the 
Connectivity Map consistently identified HSP90is as the 
highest performing compounds, thus raising the possibility 
of a functional relationship between HSP90 inhibition and 
induction of HR deficiency. To test this hypothesis, we 
first accessed publicly available microarray data of the 
transcriptional response of cancer cell lines to the HSP90i 
17-AAG, and found that exposure to 17-AAG statistically 
significantly  downregulated  HR,  ATM  and  Fanconi 
Anemia signaling pathways both at the level of the 
pathway and at the level of individual genes. Interestingly, 
this effect was only evident in the HR-proficient but not 
in HR-deficient breast cancer cells. We then confirmed 
experimentally that 17-AAG functionally suppressed HR 
pathway using both the DR-GFP reporter and RAD51 
foci formation assays after IR. Of note, even sublethal 
concentrations of 17-AAG had a significant functional 
impact on HR causing approximately 70% reduction in 
RAD51 foci formation in HR proficient ovarian cancer 
cell lines. Importantly, 17-AAG decreased BRCA1 and 
RAD51 protein levels in HR proficient EOC cells.
Given that 17-AAG suppressed HR, we assessed 
whether 17-AAG would sensitize EOC cells to platinum 
and PARPis. Indeed, we showed that the combination of 
sublethal concentrations of 17-AAG with olaparib induced 
greater DNA damage (assessed by γH2AX expression) 
compared to olaparib alone. Furthermore, sublethal 
concentrations of 17-AAG enhanced cytotoxicity of HR 
proficient EOC cells to carboplatin and olaparib. Of note, 
17-AAG also enhanced sensitivity to the combination 
of olaparib and carboplatin inducing significant killing 
even with very low olaparib and carboplatin doses 
(Supplementary Figure 2). Conversely, 17-AAG did not 
enhance cytotoxicity of the HR deficient OVCAR8 cell 
line to carboplatin and olaparib. This finding strongly 
suggests that the 17-AAG induced sensitization to olaparib 
and carboplatin is related to suppression of HR and not due 
to another (HR-independent) mechanism. Although our 
data suggest that 17-AAG suppresses HR and sensitizes 
to olaparib and carboplatin in vitro, we would like to 
recognize that 17-AAG-induced sensitization to platinum 
and PARP-inhibitors need to be further confirmed using 
in vivo models.
It is important to underscore that the 17-AAG doses 
of 10-100nM that were used in our experiments were 
sublethal in the ovarian cancer cell lines employed in our 
study although they are reportedly fully cytostatic in other 
settings (Ref. 26-28). One reason may be because HSP90-
inhibitors induce HSP70 (a known pharmacodynamic 
marker of 17-AAG therapy) which bears anti-apoptotic 
effects [26-28]. Therefore, 17-AAG may exert dual effects 
on cell death that is cell-context-dependent and dependent 
on drug combinations [26].
In conclusion, sublethal concentrations of the 
HSP90i 17-AAG suppress HR and enhance sensitivity 
of HR proficient ovarian cancer cells to platinum and 
PARPis. These results provide a preclinical rationale 
for using a combination of 17-AAG and olaparib and/
or carboplatin in EOCs that are HR proficient either at 
baseline or at the time of development of platinum or 
PARPi resistance. 
MATERIALS AND METHODS
Connectivity Map Analysis
We used our previously developed, publicly 
available, gene expression signature of BRCAness[16] 
which assigned tumors as having a BRCAness phenotype 
(BRCAlike-BL) versus not (non-BRCAlike-NBL). In 
order to identify matching gene expression signatures 
of small molecule drugs, we queried the Connectivity 
Map using the top performing genes of the BRCAness 
signature, i.e. those that were most upregulated and 
downregulated in BL versus NBL tumors using various 
cutoffs for differential expression of these genes (i.e. 2 
fold, 1.66 fold and 1.5 fold). Small molecule drugs that 
were consistently identified via the Connectivity Map 
across all cut-offs were then selected for experimental 
validation as candidate suppressors of the HR pathway. 
Details of the Connectivity Map dataset and analytics are 
provided elsewhere [12, 13].
Microarray data analysis 
We  accessed  Agilent-014850  Whole  Human 
Genome Microarray expression data of 17-AAG treated 
breast cancer cell lines[29] that were publicly available in 
GEO (Gene Expression Omnibus, accession #23209). Raw 
data were imported and analyzed using BRB-ArrayTools 
Version: 4.2.0 - Beta_2 (Biometrics Research Branch, 
National Cancer Institute). In order to assess whether the 
gene expression profiles of control and 17-AAG treated 
breast cancer cell lines were enriched for specific pathways Oncotarget 2685 www.impactjournals.com/oncotarget
or functional groups of genes, we performed gene set 
analysis (GSA) as described by Efron and Tibshirani[30]. 
GSA is an evolution of the previously reported Gene Set 
Enrichment Analysis (GSEA) and was performed using 
the Gene Set Analysis Tool of the Biometric Research 
Branch  (BRB) Array  Tools  software.  Gene  Ontology 
assignments, Biocarta and KEGG pathways, and annotated 
gene sets from The Broad Institute Molecular Signatures 
Database (MSigDB) were analyzed. The Efron-Tibshirani 
“maxmean” test was applied to identify gene sets at a GSA 
P<0.05 significance level. 
Cell Viability assay
Cells were plated at 1000 cells per well on a 96-
well plate in sextuplicate and treated with PARP inhibitor 
and/or carboplatin with or without 17 AAG at indicated 
concentrations on the next day. After 5 days, cell viability 
was quantified by Celltiter Glo.
Homologous Recombination Reporter Assay
HR assay was performed as previously reported [17, 
18, 31]. Briefly, 0.1 X 106 U2OS cells carrying DR-GFP 
reporter were plated on a 12-well plate overnight, treated 
with 17 AAG at indicated concentrations for 24 hr, and 
transfected with 500 ng of I-SceI expression plasmid using 
Lipofectamine 2000. After 48 h, GFP-positive cells were 
assayed by FACScan.
Immunofluorescence
Cells plated on glass slides were fixed for 10 min 
with 4% (v/v) paraformaldehyde and permeabilized for 
10 min with 1% (v/v) Triton X-100 in PBS. Cells were 
rinsed with PBS and incubated with RAD51 (Santa Cruz) 
primary antibody diluted in PBS with 5% goat serum 
for 2 hrs at room temperature (RT). Cells were washed, 
incubated with secondary antibody (Alexa Fluor 488 goat 
anti-rabbit IgG, Invitrogen) diluted in PBS with 5% goat 
serum for 1 hr at RT in the dark, and washed before being 
mounted using Dapi Fuoromount-G (SouthernBiotech). 
Slides were visualized by Zeiss Axioplan microscope 
and RAD51 focus-positive cells (with > 10 foci) were 
quantified by comparing 100 cells.
Immunoblots
The immunoblots were done as described previously 
[32,  33]  with  BRCA1  (Calbiochem  #OP92),  RAD51 
(Santa Cruz #sc-8349), H2AX (Cell Signaling #2595S), 
γ-H2AX (Cell Signaling #9718S) and α-tubulin (Sigma 
#T5168) antibodies.
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